Practical Management for Use of Eculizumab in the Treatment of Severe, Refractory, Non-Thymomatous, AChR + Generalized Myasthenia Gravis: A Systematic Review [Erratum]

Abstract

Waheed W, Newman E, Aboukhatwa M, Moin M, Tandan R. Ther Clin Risk Manag. 2022;18:699–719. The authors have advised there is an error in Table 1 on page 712. The value “1200 mg” in the Neisseria meningitidis vaccination row for the Induction Phase, Week 4 column for Refractory gMG Adult (≥18 years of age) Dosing Schedule, should read “900 mg”. This error was introduced by the Editorial staff during the publication process.

Keywords

• myasthenia gravis
• pathophysiology
• autoantibodies
• complement
• eculizumab